About the Event
Currently more than a billion people in the world suffer from Obstructive Sleep Apnea, a condition that makes sleep difficult and can contribute to several issues including high blood pressure, Type 2 diabetes, liver problems, and severe fatigue. In fact, a recent study showed that people with sleep apnea were nearly 2.5 times more likely to be in a car wreck than the general population.
Yet, fewer than 5% of sufferers receive treatment – and most of those use CPAP machines which are so noisy, cumbersome, and inconvenient most patients discontinue use after just a few months.
To combat these problems, Sommetrics has created aerSleep II, a maskless, medical device that uses negative pressure to open the airway allowing users to breath freely while they sleep. Sommetrics has launched a pivotal clinical study and will have results in six months. Once approved the prescription device will be in market via major drug and retail chains including CVS, Walgreens, Walmart, and others in the second half of 2023.
Join our webinar to hear from Sommetrics founder and CEO, Richard Rose, as he shares details of why aerSleep II is a significant improvement over CPAPs and how they intend to make inroads in the $6B sleep apnea market.